ClinicalTrials.gg
CompletedNCT02234115Updated Mar 5, 2019Results posted

Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma

A Phase 3 interventional study of Leuprolide Mesylate in Prostatic Neoplasms, sponsored by Foresee Pharmaceuticals Co., Ltd.. Completed at 29 sites in 8 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-03-05.

Sponsored by Foresee Pharmaceuticals Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
137
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,596 studies in Prostatic Neoplasms with a site in United States — 608 open to participants now, 977 under way, 101 of them phase 3. Prostatic Neoplasms · United States.

Enrollment
717th of 3,023
137 · median 48
Started
2014
with 142 others
Phase 3
284 of 3,596
42 open now
Registered
1,671st of 3,596
by date

Among the 3,596 studies in Prostatic Neoplasms with a site in United States, this one is the 717th largest by enrollment of the 3,023 interventional ones that give a count, is one of 143 that started in 2014, is one of 284 in phase 3, and was the 1,671st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

608 of the 3,596 studies in Prostatic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

603 more — sign in →

All 608 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,596 studies in Prostatic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The study will evaluate if Leuprolide Mesylate is safe and effective in the treatment of subjects with advanced prostate carcinoma, when administered as two injections six months apart.

Read the detailed description

This is a multi-center, open-label, single-arm study conducted in 2 parts. Part I was established to provide a vanguard of the first 30 subjects who will have more frequent monitoring of their safety. If safety is established, the remainder of the subjects will be entered into the clinical study (i.e., Part II). All subjects will be males with advanced prostate carcinoma judged to be candidates for medical androgen ablation therapy, and all will receive two injections of LMIS 50 mg six-month apart in an unblinded fashion.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Prostate Neoplasm Cancer Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males aged ≥ 18 years old
  2. Males with confirmed carcinoma of the prostate
  3. Subjects who are judged by the attending physician and/or Principal Investigator to be a candidate for androgen ablation therapy
  4. Baseline morning serum testosterone level > 150 ng/dL performed at Screening Visit
  5. (ECOG) Performance score ≤ 2
  6. of at least 18 months
  7. Laboratory values

    • ≥ 1,500 cells/µL
    • ≥ 100,000 cells/µL
    • ≥ 10 gm/dL
    • Total ≤ 1.5 × (ULN)
    • (SGOT) ≤ 2.5 × ULN
    • ALT (SGPT) ≤ 2.5 × ULN
    • Serum creatinine ≤ 1.5 mg/dL
    • Lipid profile within acceptable range according to investigator's judgment
    • HgbA1c within acceptable range according to investigator's judgment
    • Clinical chemistries (K, Na, Mg, Ca and P) within acceptable range according to investigator's judgment
    • Serum glucose within acceptable range according to investigator's judgement
    • Urinalysis within normal range according to the investigator's judgment
  8. Agree to use male methods during study trial
  9. Based on the Investigator's judgment, the ability to understand the nature of the study and any hazards of participation, and to communicate satisfactorily with the Investigator and to participate in, and to comply with, the requirements of the entire protocol
  10. All aspects of the protocol explained and written obtained

Exclusion criteria

Exclusion Criteria:

  • Receipt of chemotherapy, immunotherapy, cryotherapy, radiotherapy, or anti- androgen therapy concomitantly, or within 8 weeks prior to Screening Visit, for treatment of carcinoma of the prostate. Radiation for pain control will be allowed during the study.
  • Receipt of any vaccination (including influenza) within 4 weeks of Baseline
  • History of blood donation within 2 months of Baseline
  • History of anaphylaxis to any LH-RH analogues
  • Receipt of any LHRH suppressive therapy within 6 months of Baseline
  • Major surgery, including any prostatic surgery, within 4 weeks of Baseline
  • History and concomitant clinical and radiographic evidence of central nervous system/spinal cord . Subjects at risk for spinal cord compression will be excluded.
  • Clinical evidence of active urinary tract obstruction and subjects at risk for urinary obstruction
  • History of bilateral orchiectomy, adrenalectomy, or hypophysectomy
  • History or presence of hypogonadism, or receipt of exogenous testosterone supplementation within 6 months of Baseline
  • abnormal and/or history of clinically significant cardiovascular disease as judged by the investigator
  • History of drug and/or alcohol abuse within 6 months of Baseline
  • to leuprolide or an LHRH agonist as indicated on package labeling
  • Use of 5-alpha reductase inhibitor within the last 6 months of Baseline
  • History or presence of insulin-dependent diabetes mellitus (Type I). Presence of well controlled diabetes mellitus Type II will be allowed
  • Use of systemic at a dose >10 mg/d or anti-androgens
  • Use of any agent within 4 weeks of Baseline
  • Use of any over-the-counter (OTC) medication within 4 weeks of Baseline except for those listed in the permitted Concomitant Treatment section.
  • Uncontrolled intercurrent illness that would jeopardize the subject's safety, interfere with the objectives of the protocol, or limit the subject's compliance with study requirements, as determined by the Investigator in consultation with the Sponsor
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Leuprolide Mesylate 50mg

    All subjects will be males with advanced prostate carcinoma. They will be injected twice with a depot formulation containing 50 mg of Leuprolide Mesylate. The first dose on day 0 the second dose on day 168 (six months apart). Subjects will be followed until day 336.

    Drug: Leuprolide Mesylate

Interventions

06

What researchers measure

Primary outcomes

  1. Efficacy of Leuprolide Mesylate (LMIS 50mg)

    The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) following the first injection of LMIS 50 mg from Day 28 through Day 336 (remaining duration of the study).

    Time frame: baseline to 28 days, 28 days to 336 days

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    Safety analysis was based on the safety information from the laboratory evaluations, AEs, and SAEs.

    Time frame: 336 days

07

Results

Posted Apr 13, 2018

Participant flow

Participant flow — Overall Study
MilestoneLeuprolide Mesylate 50mg
Started137
Itt137
Pp124
Pk subgroup31
Completed122
Not completed15

Outcome measures

PrimaryEfficacy of Leuprolide Mesylate (LMIS 50mg)

The percentage of subjects with a serum testosterone concentration suppressed to castrate levels (≤ 50 ng/dL) following the first injection of LMIS 50 mg from Day 28 through Day 336 (remaining duration of the study).

Time frame:
baseline to 28 days, 28 days to 336 days
Reported as:
Mean · percentage of participants
Efficacy of Leuprolide Mesylate (LMIS 50mg)
percentage of participantsLeuprolide Mesylate 50mg
Efficacy of Leuprolide Mesylate (LMIS 50mg)97.0 (92.2 to 98.9)
SecondaryNumber of Participants With Adverse Events (AEs)

Safety analysis was based on the safety information from the laboratory evaluations, AEs, and SAEs.

Time frame:
336 days
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsLeuprolide Mesylate 50mg
TEAE114
Drug-related AEs85
SAE20

Adverse events

Collected over 336 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Mesylate 50mg3/137 (2.2%)20/137 (14.6%)114/137 (83.2%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventLeuprolide Mesylate 50mg
Subdural haematomaInjury, poisoning and procedural complications2/137
Angina pectorisCardiac disorders1/137
Atrial fibrillationCardiac disorders1/137
Myocardial infarctionCardiac disorders1/137
VertigoEar and labyrinth disorders1/137
Vision blurredEye disorders1/137
DysphagiaGastrointestinal disorders1/137
AstheniaGeneral disorders1/137
DeathGeneral disorders1/137
Non-cardiac chest painGeneral disorders1/137
Most frequent other events
Most frequent other events
EventLeuprolide Mesylate 50mg
Hot flushVascular disorders67/137
HypertensionVascular disorders20/137
Pain in extremityMusculoskeletal and connective tissue disorders13/137
Injection site painGeneral disorders10/137
FatigueGeneral disorders9/137
ArthralgiaMusculoskeletal and connective tissue disorders9/137
NocturiaRenal and urinary disorders8/137
NasopharyngitisInfections and infestations7/137
Back painMusculoskeletal and connective tissue disorders7/137

Baseline characteristics

Age, Continuous
Age, Continuous(years)Leuprolide Mesylate 50mg
Mean71.1 ± 8.70
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Mesylate 50mg
Female0
Male137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Leuprolide Mesylate 50mg
Hispanic or Latino3
Not Hispanic or Latino61
Unknown or Not Reported73
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Leuprolide Mesylate 50mg
American Indian or Alaska Native0
Asian5
Native Hawaiian or Other Pacific Islander0
Black or African American8
White123
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Leuprolide Mesylate 50mg
Austria1
United States64
Czechia17
Taiwan2
Poland5
Slovakia18
Lithuania29
Germany1
08

Study locations

29 sites
  • Urology Centers of Alabama
    Homewood, Alabama 35209, United States
  • Alliance Research Centers
    Laguna Hills, California 92653, United States
  • Genesis Research, LLC
    San Diego, California 92123, United States
  • Idaho Urologic Institute - Meridian
    Meridian, Idaho 83642, United States
  • AdvanceMed Research
    Lawrenceville, New Jersey 08648, United States
  • Carolina Clinical Trials, LLC
    Concord, North Carolina 28025, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Seattle Urology Research Center
    Burien, Washington 98166, United States
  • AKH Linz GmbH, Department of Urology
    Linz, Oberösterreich 4020, Austria
  • Universitätsklinik für Urologie und Andrologie, Landeskrankenhaus Salzburg (University hospital for Urology and Andrology)
    Salzburg, 5020, Austria
  • Thomayerova nemocnice Urologické oddělení
    Praha, Praha 4 - Krč 140 59, Czechia
  • University Hospital Hradec Králové
    Hradec Králové, 500 05, Czechia
  • University Hospital Olomouc
    Olomouc, 779 00, Czechia
  • Universitätsklinikum RWTH Aachen, Klinik für Urologie
    Aachen, Nordrhein-Westfalen 52074, Germany
  • PI Hospital of Lithuanian University of Health Sciences, Kauno Klinikos
    Kaunas, 50009, Lithuania
  • PI Klaipėda University Hospital
    Klaipėda, 92288, Lithuania
  • PI Vilnius University Hospital, Santariškių Klinikos
    Vilnius, 08661, Lithuania
  • Uniwersyteckie Centrum Kliniczne, Klinika Urologii
    Gdańsk, 80-402, Poland
  • Centralny Szpital Kliniczny MSW w Warszawie, Klinika Urologii i Urologii Onkologicznej
    Warzawa, 02-507, Poland
  • Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Układu Moczowego
    Warzawa, 02-781, Poland
  • "DERMED" Centrum Medyczne Sp. z o.o.
    Łódź, 90-265, Poland
  • UROCENTRUM MILAB, s.r.o.
    Prešov, Slovakia
  • Fakultná nemocnica s poliklinikou Žilina Urológia
    Žilina, 012 07, Slovakia
  • Kaohsiung Veteran General Hospital (VGHKS)
    Kaohsiung City, Pingtung 813, Taiwan
  • China Medical University Hospital (CMUH)
    Taichung City, Taichung 404, Taiwan
  • Taichung Veteran General Hospital (VGHTC)
    Taichung City, Taichung 407, Taiwan
  • National Cheng Kung University Hospital (NCKUH)
    Tainan City, Tainan 704, Taiwan
  • National Taiwan University Hospital (NTUH)
    Taipei City, Taipei 100, Taiwan
  • Chang Gung Memorial Hospital, LinKou (CGMH-LK)
    Taoyuan City, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Aug 2016 and a completion of Jan 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2014
First posted
Sep 9, 2014
Start
Aug 2014
Primary completionActual
Aug 30, 2016
CompletionActual
Jan 5, 2017
Results first posted
Apr 13, 2018
Last update
Mar 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02234115
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Responsible party
Sponsor
First posted
Sep 9, 2014
Start date
Aug 2014
Primary completion
Aug 30, 2016
Completion
Jan 5, 2017
Results posted
Apr 13, 2018
Last update
Mar 5, 2019

Study contacts

John Mao, PhD
study director · Foresee Pharmaceuticals Co., Ltd.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide mesylate

Start the discussion